Lymphir - HCP resource
Clinical-reference information for healthcare professionals evaluating Lymphir for international NPP requests.
Indication (US FDA label)
R/R CTCL. Refer to the manufacturer's US Prescribing Information for the full label.
Modality and mechanism
IL-2 fusion toxin.
Clinical justification for NPP
When Lymphir is not locally registered, NPP justification typically includes:
- Confirmed diagnosis meeting the US-label indication.
- Failure, intolerance, or inappropriateness of locally available alternatives.
- Treating-physician attestation of clinical appropriateness.
- Patient consent and understanding of off-label or unregistered status in-country.
Supply provenance
Reserve Meds sources Lymphir exclusively from DSCSA-compliant US specialty wholesalers. All product is US-FDA-supply-chain provenance with transaction history documentation.
Cold-chain and logistics
If Lymphir requires refrigerated or cryogenic storage, validated cold-chain shipping is standard. Receipt at hospital pharmacy is documented with temperature logs.
Pharmacovigilance
Adverse-event reports for cross-border NPP should be routed to both the local regulator and the US manufacturer. Reserve Meds supports AE-reporting coordination.
Re-supply for chronic therapy
For chronic-therapy indications, renewed prescription and NPP authorisation are coordinated per local regulator cadence.
Questions from physicians
- What documentation does the local regulator require?
- What is the typical timeline from prescription to patient receipt?
- What is the patient's out-of-pocket cost?
- How is the drug authenticated on arrival?
- How do I report adverse events?
Contact the clinical team at [email protected].